160 related articles for article (PubMed ID: 18680550)
1. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.
Chu CJ; Lee SD; Hung TH; Lin HC; Hwang SJ; Lee FY; Lu RH; Yu MI; Chang CY; Yang PL; Lee CY; Chang FY
Aliment Pharmacol Ther; 2009 Jan; 29(1):46-54. PubMed ID: 18680550
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M; Del Mar Viloria M; Andrade RJ; Salmerón J; Diago M; Fernández-Rodríguez CM; Corpas R; Cruz M; Grande L; Vázquez L; Muñoz-De-Rueda P; López-Serrano P; Gila A; Gutiérrez ML; Pérez C; Ruiz-Extremera A; Suárez E; Castillo J
Gastroenterology; 2005 Mar; 128(3):636-41. PubMed ID: 15765399
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M
Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance impairs viral dynamics independently of ethnicity or genotypes.
Eslam M; Aparcero R; Mousa YI; Grande L; Shaker Y; Ali A; Del Campo JA; Khattab MA; Romero-Gomez M
J Clin Gastroenterol; 2012 Mar; 46(3):228-34. PubMed ID: 22298085
[TBL] [Abstract][Full Text] [Related]
6. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients.
Fattovich G; Covolo L; Pasino M; Perini E; Rossi L; Brocco G; Guido M; Cristofori C; Belotti C; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Minola E; Negro F; Donato F;
Liver Int; 2011 Jan; 31(1):66-74. PubMed ID: 20840397
[TBL] [Abstract][Full Text] [Related]
7. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Int J Infect Dis; 2012 Jun; 16(6):e436-41. PubMed ID: 22486858
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
[TBL] [Abstract][Full Text] [Related]
9. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.
Jung HJ; Kim YS; Kim SG; Lee YN; Jeong SW; Jang JY; Lee SH; Kim HS; Kim BS
Clin Mol Hepatol; 2014 Mar; 20(1):38-46. PubMed ID: 24757657
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
Huang JF; Dai CY; Yu ML; Huang CF; Huang CI; Yeh ML; Yang JF; Hou NJ; Hsiao PJ; Lin ZY; Chen SC; Shin SJ; Chuang WL
Liver Int; 2011 Sep; 31(8):1155-62. PubMed ID: 21745292
[TBL] [Abstract][Full Text] [Related]
14. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T
World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
Hsu CS; Hsu SJ; Lin HH; Tseng TC; Wang CC; Chen DS; Kao JH
J Formos Med Assoc; 2014 Oct; 113(10):716-21. PubMed ID: 24974131
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.
Moucari R; Ripault MP; Martinot-Peignoux M; Voitot H; Cardoso AC; Stern C; Boyer N; Maylin S; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
Gut; 2009 Dec; 58(12):1662-9. PubMed ID: 19671541
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
[TBL] [Abstract][Full Text] [Related]
18. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.
Miyase S; Haraoka K; Ouchida Y; Morishita Y; Fujiyama S
J Gastroenterol; 2012 Sep; 47(9):1014-21. PubMed ID: 22382633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]